drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody immunotherapy (biologic)
drug_description
A chimeric IgG1 anti-GD2 monoclonal antibody immunotherapy (brand: Qarziba) used as maintenance after response in relapsed/refractory high‑grade osteosarcoma. It binds the disialoganglioside GD2 on tumor cells and triggers immune effector killing via Fc-mediated ADCC and phagocytosis, and complement‑dependent cytotoxicity (CDC). Dosed as continuous IV 14 mg/m2/day on days 1–5 every 28 days for 5 cycles.
nci_thesaurus_concept_id
C1570
nci_thesaurus_preferred_term
Dinutuximab
nci_thesaurus_definition
A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Dinutuximab binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells. GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung.
drug_mesh_term
Dinutuximab
drug_category
CYTOTOXIC ANTIBODY
drug_class
General immune activator
drug_delivery_route
Intravenous
drug_mechanism_of_action
Chimeric IgG1 anti-GD2 monoclonal antibody that binds GD2 on tumor cells and elicits immune effector killing via Fcγ receptor–mediated ADCC and phagocytosis, and complement-dependent cytotoxicity (CDC).
drug_name
Dinutuximab beta
nct_id_drug_ref
NCT05558280